Summary by Futu AI
Cormorant Asset Management, LP has completed a significant acquisition of shares in EyePoint Pharmaceuticals, Inc. (EYPT). On April 18, 2024, the asset management firm purchased a total of 581,765 shares of common stock in two separate transactions. The first transaction involved the purchase of 395,244 shares at a price of $17.62 per share, while the second transaction saw the acquisition of 186,521 shares at $18.90 each. Following these transactions, Cormorant Asset Management's total beneficial ownership in EyePoint Pharmaceuticals has risen to 7,475,000 shares. The transactions were executed on the open market and are part of the firm's investment strategy.